Telum Therapeutics appoints Subhendu Basu CEO
Telum Therapeutics nombra a Subhendu Basu Consejero Delegado
Intel ID : 388901
Relevant Documents
| Press Release | 19 Mar 2024 | Telum_Therapeutics_Nota_de_Prensa_2024.pdf | EN |
|
| Intel ID | 388901 | |
| Value | ND | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Telum Therapeutics
(31 Dec 2023) |
Revenue: - Net Debt: - |
|
| Date |
 |
|
| Country |  |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
30.01.99 Other Biotechnology & Pharmaceuticals (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.99 Other Biotechnology & Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.